Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 Weeks

October 2025 in “ Electronic Theses and Dissertations Repository (University of Pisa) ”

SALVIA, GIORGIA

baricitinib alopecia areata lipid profile inflammatory indices NLR PLR

TLDR Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

The study investigated the effects of baricitinib on lipid profiles and hematologic inflammation indices in 37 patients with severe alopecia areata over 52 weeks. The treatment was well tolerated, with 73% of patients responding to baricitinib. Lipid profile changes were modest, with a significant increase in total cholesterol but non-significant fluctuations in LDL, HDL, and triglycerides. Among inflammatory indices, only the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) showed significant changes, with PLR being higher in responders and emerging as the most sensitive marker of treatment response. Overall, the study concluded that baricitinib led to minor metabolic and hematologic variations, which were not clinically significant.

View this study on etd.adm.unipi.it →

Discuss this study in the Community →

Related Community Posts Join

6 / 15 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?

in Chat 45 upvotes 3 weeks ago

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 2 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 20 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 6 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

Similar Research

5 / 615 results

research Recent Advances in Drug Development for Hair Loss

April 2025 in “International Journal of Molecular Sciences”

New treatments for hair loss show promise with advanced therapies and better targeting.

research Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders

January 2025 in “International Journal of Molecular Sciences”

Psoriasis involves immune and genetic factors, and understanding these can improve treatments.